Vertex Pharmaceuticals Inc / Ma revenue by segment VRTX

Annual Quarterly

Vertex Pharmaceuticals Inc / Ma splits its revenue into 10 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was TRIKAFTAKAFTRIO at $10.3 billion, 86% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	12,952	12,001	11,020	9,869	8,931	7,574	6,206	4,163	3,048	2,489	1,702
TRIKAFTAKAFTRIO	—	10,313 +0.7% share 85.9%	10,239 +14.5% share 92.9%	8,945 +16.4% share 90.6%	7,687 +34.9% share 86.1%	5,697 +47.5% share 75.2%	3,864 +819.7% share 62.3%	420 share 10.1%	—	—	—
ALYFTREK	—	838 share 7.0%	—	—	—	—	—	—	—	—	—
Manufactured Product Other	—	820 +4.9% share 6.8%	782 share 7.1%	—	—	—	—	—	—	—	—
Kalydeco	—	—	—	476 -14.0% share 4.8%	553 -19.1% share 6.2%	684 -14.8% share 9.0%	803 -19.0% share 12.9%	991 -1.6% share 23.8%	1,008 +19.3% share 33.1%	845 share 33.9%	—
TRIKAFTA	—	—	—	—	—	—	—	420 share 10.1%	—	—	—
ORKAMBI	—	—	—	326 -36.2% share 3.3%	511 -33.8% share 5.7%	772 -15.0% share 10.2%	908 -31.9% share 14.6%	1,332 +5.5% share 32.0%	1,262 -4.4% share 41.4%	1,321 share 53.1%	—
SYMDEKOSYMKEVI	—	—	—	123 -31.7% share 1.2%	180 -57.2% share 2.0%	420 -33.1% share 5.6%	629 -55.7% share 10.1%	1,418 +84.4% share 34.1%	769 share 25.2%	—	—
CASGEVY	—	116 +1058.0% share 1.0%	10 share 0.1%	—	—	—	—	—	—	—	—
JOURNAVX	—	60 share 0.5%	—	—	—	—	—	—	—	—	—
Collaborativeand Royalty	—	31 share 0.3%	—	—	—	1 -65.5% share 0.0%	3 +38.1% share 0.0%	2 -77.4% share 0.1%	9 -97.1% share 0.3%	323 share 13.0%	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: VRTX (Nasdaq)
Fiscal year ends: December 31
Incorporated in: MA
Headquarters: Boston, MA
SEC filer status: Large accelerated filer
SEC CIK: 875320

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.